360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

enoxaparin

Type: Keyphrase

Name: enoxaparin

First reported May 16 2013 - Updated May 16 2013 - 1 reports

FDA Food & Drug Administration

Momenta Pharmaceuticals Management Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)

Momenta Pharmaceuticals, Inc. (MNTA) Bank of America Merrill Lynch Health Care Conference Call May 15, 2013 7:20 PM ETSumant Kulkarni – Bank of America/Merrill LynchOne of the specialty pharma analysts within Gregg Gilbert's US major pharma and specialty ... [Published Seeking Alpha - May 16 2013]

Entities: FDA Food & Drug Administration, Patent, Momenta Pharmaceuticals Inc

First reported May 13 2013 - Updated May 13 2013 - 1 reports

A microfluidic anti-Factor Xa assay device for point of care monitoring of anticoagulation therapy

The development of new point of care coagulation assay devices is necessary due to the increasing number of patients requiring long-term anticoagulation in addition to the desire for appropriate, targeted anticoagulant therapy and a more rapid response ... [Published RSC - May 13 2013]

Entities: Assay, enoxaparin, Anticoagulant, Capillary

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Tamiflu Leads Q1 Drug Sales Growth

In the first quarter of 2013, the rankings for the top five drugs by sales shifted a bit, but exhibited positive growth for the quarter, according to a report released by Drugs.com. Abilify, Otsuka's second generation antipsychotic, and Nexium, AstraZeneca's ... [Published Pharmaceutical Technology - May 07 2013]

Entities: Tamiflu, Drugs, Avonex, Modafinil, Abilify

First reported May 02 2013 - Updated May 03 2013 - 1 reports

Sanofi profits plunge but forecasts strong second half

As expected, Sanofi's earnings for the first quarter have been battered by generics, though the French drugmaker's diabetes drugs and vaccines helped soften the blow.Business net income, which excludes items, fell 33.5% to 1.61 billion euros (at constant ... [Published Pharma Times - May 02 2013]

Entities: Sanofi SA, Lovenox, Eloxatin, Chris Viehbacher, Avapro

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Momenta Pharmaceuticals Inc

Momenta Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript

Momenta Pharmaceuticals, Inc. (MNTA) Q1 2013 Earnings Call April 30, 2013 10:00 AM ETOperatorGood day, ladies and gentlemen, and thank you for your patience. You’ve joined the Momenta Pharmaceuticals First Quarter 2013 Financial Results Conference Call. ... [Published Seeking Alpha - Apr 30 2013]

Entities: enoxaparin, Sandoz, Momenta Pharmaceuticals Inc, Amphastar Pharmaceuticals Inc

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Sanofi SA

Court Rules in Novel False Claims Act Case Where One Pharmaceutical Company Sues Another

By Delia A. Stubbs – The U.S. District Court for the Eastern District of California issued a ruling last week in an unusual, if not unprecedented, case arising from alleged federal False Claims Act (“FCA”) violations where one drug manufacture has sued ... [Published FDA Law Blog - Apr 25 2013]

Entities: Sanofi SA, Amphastar Pharmaceuticals Inc, enoxaparin, Lovenox

First reported Apr 23 2013 - Updated Apr 23 2013 - 1 reports

Parts 1

A 57-year-old man presented to the emergency department (ED) with a two-day history of worsening shortness of breath, light-headedness, and back pain. The patient, who had a history of ankylosing spondylitis, had been receiving weekly therapy from a chiropractor ... [Published Clinician Reviews - Apr 23 2013]

Entities: cervical, Catheter, dyspnea

First reported Apr 22 2013 - Updated Apr 22 2013 - 1 reports

Sanofi unleashes iPhone app for heparin dosing

Sanofi's unit in Spain has unleashed a mobile app called CLX Dosis for calculating doses of its anticoagulant Clexane (enoxaparin). As PMLive reports, the French drug giant ($SNY) has developed the dosing calculator for Apple's ($APPL) iPhone and iPad ... [Published FiercePharma - Apr 22 2013]

Entities: Sanofi SA, Heparin, iPhone, Anticoagulant

First reported Apr 19 2013 - Updated Apr 19 2013 - 1 reports

A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: double-blinded, randomised controlled trial

IntroductionCritically ill patients are predisposed to venous thromboembolism. We hypothesized that higher doses of enoxaparin would improve thromboprophylaxis without increasing the risk of bleeding. Peak anti-factor Xa (anti-Xa) levels of 0.1- 0.4 IU/ml, ... [Published Critical Care - Apr 19 2013]

Entities: enoxaparin, double-blinded, Antithrombin, Fibrinogen

First reported Apr 13 2013 - Updated Apr 13 2013 - 1 reports

Portola Pharma Files for IPO, Progresses Anticoagulant Through Phase III Trials

Brian Gormley and Kristin Jones,(c) 2013 Dow Jones & Company, Inc.Portola Pharmaceuticals Inc ., which is running a large Phase III clinical trial of an anticoagulant that may prevent dangerous blood clots in patients with certain serious illnesses, has ... [Published Dow Jones Financial Information Services - Apr 13 2013]

Entities: Betrixaban, Portola Pharmaceuticals Inc, enoxaparin

First reported Apr 01 2013 - Updated Apr 01 2013 - 1 reports

ENOXAPARIN SODIUMinjection [Winthrop U.S.]

Updated Date: Apr 1, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Apr 01 2013]

Entities: enoxaparin, United States

First reported Mar 19 2013 - Updated Mar 19 2013 - 1 reports

ENOXAPARIN SODIUMinjection [Amphastar Pharmaceuticals, Inc.]

Updated Date: Mar 19, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Mar 19 2013]

Entities: Amphastar Pharmaceuticals Inc, enoxaparin

Quotes

Abilify sales grew 3.2% over the previous quarter; Nexium's sales increased 1.2%. Cymbalta, Eli Lilly "s depression and pain agent, moved past Crestor, AstraZeneca's leading statin, even as Cymbalta faces end-of-year patent loss. Advair Diskus, GlaxoSmithKline's cornerstone asthma and COPD inhaler, grabbed the fifth spot."

Tamiflu Leads Q1 Drug Sales Growth [Published Pharmaceutical Technology - May 07 2013]

..."Seasonal fluctuations in pharmaceutical sales are common, particularly in cold, flu and allergy seasons," said Philip Thornton, CEO of Drugs.com. "This year's flu activity, which started about four weeks early and was relatively severe, is evident in the Tamiflu numbers." Top Five Sales Losses, Q1 2013 Drug Name Loss ($000) % Change (previous quarter) modafinil -$46,169 -17.44% Avonex -$33,647 -9...

Drugs.com Releases Q1 Sales for Top 100 U.S. Drugs: Rough U.S Flu Season Boosts Numbers for Tamiflu [Published TickerTech.com - May 06 2013]

Chief executive Chris Viehbacher (pictured) was upbeat, saying Sanofi's growth platforms "continue to deliver strong results with diabetes, vaccines, and Genzyme all achieving double-digit growth" . He added that the early launch trends for the multiple sclerosis pill Aubagio (teriflunomide), which brought in 20 million euros, and Auvi-Q (epinephrine...

Sanofi profits plunge but forecasts strong second half [Published Pharma Times - May 02 2013]

...Transit was delayed in ten of these eleven subjects. The authors observed: "when there was delayed esophageal transit of tablets, the initial absorption of acetaminophen (measured as AUC over the first 60 min) was lower than that after normal esophageal transit of tablets. The peak plasma acetaminophen concentration was also lower and occurred 90 min later when transit was delayed. These kinetic changes decrease the effectiveness of acetaminophen as an analgesic." See K S Channer and C J Roberts, "Effect of Delayed Esophageal Transit on Acetaminophen Absorption" Clinical Pharmacology and Therapeutics 37, 72-76...

Solid dosage form that promotes reliable oral, esophageal and GI transit [Published PharmCast - Mar 14 2013]

More Content

sort by: Date \| Relevance
IPO Preview: Portola Pharmaceuticals [Published Seeking Alpha - 2 hours ago]
Momenta Pharmaceuticals Management Presents at ... [Published Seeking Alpha - May 16 2013]
A microfluidic anti-Factor Xa assay device for ... [Published RSC - May 13 2013]
Management's Discussion and Analysis of Financi... [Published Pharmacy Choice - May 11 2013]
Tamiflu Leads Q1 Drug Sales Growth [Published Pharmaceutical Technology - May 07 2013]
Drugs.com Releases Q1 Sales for Top 100 U.S. Dr... [Published TickerTech.com - May 06 2013]
Sanofi profits plunge but forecasts strong seco... [Published Pharma Times - May 02 2013]
Momenta Pharmaceuticals' CEO Discusses Q1 2013 ... [Published Seeking Alpha - Apr 30 2013]
Court Rules in Novel False Claims Act Case Wher... [Published FDA Law Blog - Apr 25 2013]
Parts 1 [Published Clinician Reviews - Apr 23 2013]
News from the American College of Cardiology Sc... [Published British Journal of Cardiology - Apr 23 2013]
Sanofi unleashes iPhone app for heparin dosing [Published FiercePharma - Apr 22 2013]
A comparative study of varying doses of enoxapa... [Published Critical Care - Apr 19 2013]
Drugs - verteporfin - usage, dosage, interacti... [Published AARP - Segunda Juventud - Apr 14 2013]
Portola Pharma Files for IPO, Progresses Antico... [Published Dow Jones Financial Information Services - Apr 13 2013]
ENOXAPARIN SODIUMinjection [Winthrop U.S.] [Published DailyMed Drug Label Updates for the last seven ... - Apr 01 2013]
ENOXAPARIN SODIUMinjection [Amphastar Pharmaceu... [Published DailyMed Drug Label Updates for the last seven ... - Mar 19 2013]
Solid dosage form that promotes reliable oral, ... [Published PharmCast - Mar 14 2013]
U.S. Supreme Court Asked to Review Hatch-Waxman... [Published FDA Law Blog - Feb 25 2013]
MKSAP: 28-year-old man with left calf deep veno... [Published KevinMD.com - Feb 23 2013]
No net benefit with rivaroxaban for hospital pa... [Published BioPortfolio - Feb 07 2013]
VTE Risk Falls, Bleeds Rise with Longer Prophyl... [Published MedPageToday.com - medical news plus CME for ph ... - Feb 06 2013]
ENOXAPARIN SODIUMinjection [Amphastar Pharmaceu... [Published DailyMed Drug Label Updates for the last seven ... - Jan 16 2013]
ENOXAPARIN SODIUMinjection [Amphastar Pharmaceu... [Published DailyMed Drug Label Updates for the last seven ... - Jan 11 2013]
Portola, BMS and Pfizer ink pact to conduct pro... [Published PharmaBiz - Nov 03 2012]
CHMP recommends approval of Bayerâs Xarelto to ... [Published PharmaBiz - Oct 22 2012]
Fact Sheet for Haike Chemical Group Ltd [Published Able2Act - Mar 06 2008]

Blogs

sort by: Date \| Relevance
Court Rules in Novel False Claims Act Case Wher... [Published FDA Law Blog - Apr 25 2013] By Delia A. Stubbs – The U.S. District Court for the Eastern District of California issued a ruling last week in an unusual, if not unprecedented, case arising from alleged federal False Claims Act (“FCA”) violations where one drug manufacture has sued ...
ENOXAPARIN SODIUMinjection [Winthrop U.S.] [Published DailyMed Drug Label Updates for the last seven ... - Apr 01 2013] Updated Date: Apr 1, 2013 EST ...
ENOXAPARIN SODIUMinjection [Amphastar Pharmaceu... [Published DailyMed Drug Label Updates for the last seven ... - Mar 19 2013] Updated Date: Mar 19, 2013 EST ...
U.S. Supreme Court Asked to Review Hatch-Waxman... [Published FDA Law Blog - Feb 25 2013] By Kurt R. Karst –In a widely anticipated move, Momenta Pharmaceuticals, Inc. and Sandoz Inc. have petitioned the U.S. Supreme Court to review the August 3, 2012 judgment of the U.S. Court of Appeals for the Federal Circuit, in which a divided (2-1) Federal ...
MKSAP: 28-year-old man with left calf deep veno... [Published KevinMD.com - Feb 23 2013] Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians . A 28-year-old man is evaluated 24 hours after a new diagnosis of a left calf deep venous thrombosis. One week ago, he underwent orthopedic ...